Phase 2 clinical trial of primary systemic therapy for primary breast cancer Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer

Phase 2 clinical trial of primary systemic therapy for primary breast cancer Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer - Phase 2 clinical trial of primary systemic therapy for breast cancer Nab-Paclitaxel followed by EC for HER2- breast cancer and Docetaxel/Carboplatin/Herceptin for HER2+ breast cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013513

Enrollment

100

Registered

2014-03-25

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary breast cancer

Interventions

Neoadjuvant chemotherapy using Nab-Paclitaxel followed by Epirubicin and Cyclophosphamide for HER2 negative primary breast cancer and Docetaxel/Carboplatin/Herceptin3 for HER2 positive breast cancer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Stage 2 and 3 primary breast cancer patients who are eligible for chemotherapy

Exclusion criteria

Exclusion criteria: Patients who are ineligible for chemotherapy

Design outcomes

Primary

Measure	Time frame
Rate of pathological complete response	—

Secondary

Measure	Time frame
Postsurgical histological response, Rate of breast conservative surgery, clinical response, and adverse effect DFS and overall survival Exploratory study of imaing and molecular biomarkers	—

Countries

Japan

Contacts

Public ContactShigeto UEDA

International Medical Center, Saitama Medical University Dept of breast oncology

syueda@saitma-med.ac.jp042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026